Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pluristem Therapeutc (PSTI)

Pluristem Therapeutc (PSTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,348
  • Shares Outstanding, K 32,348
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,870 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.91
  • Price/Sales 136.79
  • Price/Cash Flow N/A
  • Price/Book 0.80
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.47
  • Most Recent Earnings $-0.31 on 05/09/22
  • Next Earnings Date 09/12/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +95.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9500 +5.26%
on 07/25/22
1.3600 -26.47%
on 07/08/22
-0.2700 (-21.26%)
since 06/24/22
3-Month
0.9500 +5.26%
on 07/25/22
1.7800 -43.82%
on 04/26/22
-0.7400 (-42.53%)
since 04/25/22
52-Week
0.9500 +5.26%
on 07/25/22
3.4500 -71.01%
on 07/28/21
-2.4300 (-70.85%)
since 07/23/21

Most Recent Stories

More News
Pluri CEO Issues Shareholder Update

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem...

PSTI : 1.0000 (-2.91%)
PLUR.VN : 0.420 (+2.44%)
PLUR : 4.55 (-5.60%)
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based...

PSTI : 1.0000 (-2.91%)
PLUR.VN : 0.420 (+2.44%)
PLUR : 4.55 (-5.60%)
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14...

PSTI : 1.0000 (-2.91%)
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of...

PSTI : 1.0000 (-2.91%)
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell...

PSTI : 1.0000 (-2.91%)
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”),...

PSTI : 1.0000 (-2.91%)
Pluristem: Fiscal Q2 Earnings Snapshot

HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Monday reported a loss of $10.9 million in its fiscal second quarter.

PSTI : 1.0000 (-2.91%)
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power...

PSTI : 1.0000 (-2.91%)
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company,...

PSTI : 1.0000 (-2.91%)
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 3.37 (-0.88%)
ATNM : 1.2150 (-5.81%)
ADCO.TO : 0.1700 (+6.25%)
ADCOF : 0.1126 (+3.30%)
ALIM : 5.54 (-0.18%)
ACOGF : 8.7500 (-7.89%)
AMST : 5.10 (-0.20%)
ANVS : 4.45 (+1.83%)
ANPC : 4.37 (-5.41%)
ARC : 3.39 (unch)

Business Summary

PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use,...

See More

Key Turning Points

3rd Resistance Point 1.1500
2nd Resistance Point 1.1000
1st Resistance Point 1.0500
Last Price 1.0000
1st Support Level 0.9500
2nd Support Level 0.9000
3rd Support Level 0.8500

See More

52-Week High 3.4500
Fibonacci 61.8% 2.4950
Fibonacci 50% 2.2000
Fibonacci 38.2% 1.9050
Last Price 1.0000
52-Week Low 0.9500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar